全文获取类型
收费全文 | 750篇 |
免费 | 38篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 48篇 |
口腔科学 | 1篇 |
临床医学 | 20篇 |
内科学 | 150篇 |
皮肤病学 | 121篇 |
神经病学 | 10篇 |
特种医学 | 20篇 |
外科学 | 147篇 |
综合类 | 16篇 |
预防医学 | 9篇 |
眼科学 | 6篇 |
药学 | 20篇 |
肿瘤学 | 214篇 |
出版年
2023年 | 9篇 |
2022年 | 3篇 |
2021年 | 15篇 |
2020年 | 9篇 |
2019年 | 15篇 |
2018年 | 28篇 |
2017年 | 18篇 |
2016年 | 22篇 |
2015年 | 18篇 |
2014年 | 17篇 |
2013年 | 23篇 |
2012年 | 54篇 |
2011年 | 58篇 |
2010年 | 41篇 |
2009年 | 21篇 |
2008年 | 44篇 |
2007年 | 46篇 |
2006年 | 50篇 |
2005年 | 41篇 |
2004年 | 37篇 |
2003年 | 27篇 |
2002年 | 38篇 |
2001年 | 21篇 |
2000年 | 31篇 |
1999年 | 15篇 |
1998年 | 6篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1995年 | 1篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 9篇 |
1988年 | 3篇 |
1987年 | 8篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 1篇 |
1982年 | 2篇 |
1978年 | 2篇 |
1976年 | 1篇 |
1947年 | 1篇 |
排序方式: 共有789条查询结果,搜索用时 15 毫秒
1.
2.
Kensei Tobinai 《Nihon rinsho. Japanese journal of clinical medicine》2002,60(1):95-99
CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric anti-CD20 monoclonal antibody with mouse variable and human constant regions. The toxicities of rituximab are mainly infusion-related, non-hematological grade 1 or 2 episodes. Of the 11 eligible patients enrolled in the phase I study in Japan, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m2 x 4 weekly infusions. The overall response rates in relapsed indolent B-cell lymphoma and mantle cell lymphoma were 61% (37/61) and 46% (6/13), respectively. Rituximab is a novel, effective anti-lymphoma agent with acceptable toxicities. 相似文献
3.
Kensei Minoda 《眼科学报》1996,(1)
Purpose: To disclose the structure of visual pigment gene for a protanopia with specific variation.Methods: Exon 5 fragments of the red andgreen visual pigment genes from the protanopia with specific varnation as well as controls were amplified by poly-merase chain reaction (PCR). The PCR products were put through heteroduplex-SSCP analysis and PCR-RFLP (restriction fragement length polymorphism) analysis to clarify the specific variation. The specific variation of the exon 5 DNA fragment from the protanopia was identified by sequencing.Results: A novel 5'green-3'red hybrid gene fragment without the normal red and green visual pigment gene was discovered in the protanopia. He should only have a single visual pigment gene, 5'green-3'red hybrid gene, on his X chromosome. The fusion point is between codon 285 and codon 296 in exon 5. Conclusion : Unequal intragenic recombination may occur in exon 5 as well as its upstream. A 5'green-3'red hybrid gene may present independently on the X chromosome without ac 相似文献
4.
Photoreceptor differentiation of retinoblastoma: An electron microscopic study of 29 retinoblastomas
Yasuo Tajima Shigeru Munakata Yasuo Ishida Tohru Nakajima Isamu Sugano Koichi Nagao Kensei Minoda Yoichiro Kondo 《Pathology international》1994,44(12):837-843
Retinoblastomas exhibit a unique form of differentiation to produce cell elements similar to those seen in a photoreceptor cell. An ultrastructural study was performed on 29 cases of retinoblastoma to further clarify the cytologic characteristics of the tumor cells. The age of the retinoblastomas averaged 17.1 months and the tumor cells showing photo-receptor differentiation were demonstrated in 10 cases (35%). The findings were especially notable in retinoblastomas with Flexner-Wintersteiner rosette formation (seven cases, 28%). Similar photoreceptor differentiation was also evident in solid cell clusters without rosette formation (four cases, 14%). The presence of photoreceptor elements was assumed to be significantly frequent both in Flexner-Wintersteiner rosettes and in the solid cell clusters. The cell cytoplasm also showed proliferation of long mitochondria and microtubules, reflecting photoreceptor differentiation. The hereditary-type retinoblastoma showed more advanced cell differentiation than the non-hereditary type. Photoreceptor differentiated retinoblastoma showed rather indolent growth compared with the undifferentiated type, and the former can expect a curative treatment by operation. These observations provide additional findings of the biological nature of retinoblastomas. 相似文献
5.
Purpose: Human leukocyte antigens (HLA) are cell surface glyco-proteins playing a key role in the immune system. In some cancers, changes in major histocompatibility complex (MHC) class I and II expression, usually a reduction or loss of these molecules, appear to provide a mechanism whereby tumour cells may escape host immunity. We investigated the relationship between HLA, especially class II, molecules and prostate cancer in Japanese men using molecular techniques.
Materials and methods: HLA class II typing was performed by the polymerase chain reaction-sequence specific primer (PCR-SSP) method of analysis and/or a commercial rapid assay based on the PCR followed by reverse dot-blot hybridization of the PCR products (Inno-LiPA assay). Allele frequencies were calculated. HLA allele frequencies reported in 1216 healthy Japanese individuals were used as the control data. Differences in allele frequency between subjects and the control group were analyzed by the chi-square test. The relationship between HLA antigens/alleles and prostate cancer is expressed in terms of relative risk (RR).
Results: The frequencies of HLA-DR4 were significantly higher in Japanese men with prostate cancer than in the healthy control group (gene frequency 36.2% vs. 26.3% in control, p<0.05), although the relative risk of prostate cancer was less than 2. Furthermore, the frequencies of HLA-DRB1-0406, 0410 and 1405 allele were significantly higher in the prostate cancer group than in the control group (allele frequency was 7.3%, 4.5% and 5.4% vs. 3.03%, 1.79% and 2.22%, p<0.05, respectively). RR of those HLA-DRB1 allele for prostate cancer was 2.6 in each allele.
Conclusions: HLA molecules may be useful for the early detection of prostate cancer as a risk factor, and also for recognizing cancer activity by using them as a marker helpful in the choice of appropriate treatment by predicting prognosis. 相似文献
6.
Human heparanase: roles in invasion and metastasis of cancer 总被引:39,自引:0,他引:39
Gohji K Katsuoka Y Okamoto M Kamidono S Kitazawa S Toyoshima M Dong J Nakajima M 《Hinyokika kiyo. Acta urologica Japonica》2000,46(10):757-762
Heparanase, which is an extracellular matrix degradative enzyme, degrades heparan sulfate and heparan sulfate proteoglycans, which are chief components of extracellular matrix and vascular basement membrane. The gene structure of this enzyme was recently determined. The biological functions of this enzyme in vivo were as follows: 1) this enzyme accelerates cancer cell invasion and metastasis though the degradation of vascular basement membrane and extracellular matrix by cancer cells; 2) this enzyme releases and activates heparin-binding growth factors such as bFGF and VEGF from heparan sulfate proteoglycans, and induces angiogenesis; 3) the degradative products of heparan sulfate proteoglycans by this enzyme suppress the biological function of activated T-lymphocytes. Therefore, heparanase is thought to be a favorable molecule for acceleration of cancer invasion and metastasis. The expression of heparanase is strongly correlated with the metastasis of melanoma and fibrosarcoma. Thus, heparanase may play important roles in invasion and metastasis of cancer. 相似文献
7.
Yosuke Ando Takahiro Hayashi Kaori Ito Eri Suzuki Naoyuki Mine Ayumi Miyamoto Miyuki Oya Hidezo Matsuda Ami Isaji Toru Nakanishi Kazuyoshi Imaizumi Tomoyuki Shibata Tatsuyoshi Okada Kazuo Sakurai Kensei Naito Ichiro Uyama Kenji Kawada Hiroshi Takahashi Shigeki Yamada 《Supportive care in cancer》2016,24(2):871-878
8.
9.
10.
Masanori Someya Masakazu Hori Kunihiko Tateoka Kensei Nakata Masaru Takagi Masato Saito Naoki Hirokawa Masato Hareyama Koh-ichi Sakata 《Journal of radiation research》2015,56(1):122-127
In patients undergoing radiotherapy for localized prostate cancer, dose–volume histograms and clinical variables were examined to search for correlations between radiation treatment planning parameters and late rectal bleeding. We analyzed 129 patients with localized prostate cancer who were managed from 2002 to 2010 at our institution. They were treated with 3D conformal radiation therapy (3D-CRT, 70 Gy/35 fractions, 55 patients) or intensity-modulated radiation therapy (IMRT, 76 Gy/38 fractions, 74 patients). All radiation treatment plans were retrospectively reconstructed, dose–volume histograms of the rectum were generated, and the doses delivered to the rectum were calculated. Time to rectal bleeding ranged from 9–53 months, with a median of 18.7 months. Of the 129 patients, 33 patients had Grade 1 bleeding and were treated with steroid suppositories, while 25 patients with Grade 2 bleeding received argon plasma laser coagulation therapy (APC). Three patients with Grade 3 bleeding required both APC and blood transfusion. The 5-year incidence rate of Grade 2 or 3 rectal bleeding was 21.8% for the 3D-CRT group and 21.6% for the IMRT group. Univariate analysis showed significant differences in the average values from V65 to V10 between Grades 0–1 and Grades 2–3. Multivariate analysis demonstrated that patients with V65 ≥ 17% had a significantly increased risk (P = 0.032) of Grade 2 or 3 rectal bleeding. Of the 28 patients of Grade 2 or 3 rectal bleeding, 17 patients (60.7%) were cured by a single session of APC, while the other 11 patients required two sessions. Thus, none of the patients had any further rectal bleeding after the second APC session. 相似文献